Open AccessCost-effectiveness of ethyl-eicosapentaenoic acid in the treatment of bipolar disorder
Author(s) -
Nadir Cheema,
Sophia Frangou,
Paul McCrone
Publication year - 2012
Publication title -
therapeutic advances in psychopharmacology
Language(s) - English
Resource type - Journals
eISSN - 2045-1261
pISSN - 2045-1253
DOI - 10.1177/2045125312464105
Subject(s) - eicosapentaenoic acid , placebo , bipolar disorder , clinical trial , medicine , quality adjusted life year , psychiatry , quality of life (healthcare) , cost effectiveness , mood , alternative medicine , fatty acid , chemistry , polyunsaturated fatty acid , organic chemistry , risk analysis (engineering) , nursing , pathology
This study develops an economic model to evaluate the cost-effectiveness of ethyl-eicosapentaenoic acid (ethyl-EPA) as an adjunct treatment of bipolar I disorder.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom